Brokers Offer Predictions for Sanofi’s Q1 2023 Earnings (NASDAQ:SNY)
Sanofi (NASDAQ:SNY – Get Rating) – Equities research analysts at SVB Leerink issued their Q1 2023 EPS estimates for shares of Sanofi in a report issued on Sunday, May 22nd. SVB Leerink analyst D. Risinger expects that the company will post earnings per share of $1.02 for the quarter. SVB Leerink currently has a “Outperform” rating on the stock. SVB Leerink also issued estimates for Sanofi’s Q1 2023 earnings at $1.02 EPS, Q2 2023 earnings at $0.94 EPS, Q2 2023 earnings at $0.94 EPS, Q3 2023 earnings at $1.32 EPS, Q3 2023 earnings at $1.32 EPS, Q4 2023 earnings at $0.97 EPS and Q4 2023 earnings at $0.97 EPS.
SNY has been the subject of several other reports. Credit Suisse Group lifted their price objective on Sanofi from €96.00 ($102.13) to €105.00 ($111.70) in a report on Monday, March 28th. Liberum Capital raised Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, January 25th. Guggenheim increased their price target on Sanofi from €121.00 ($128.72) to €127.00 ($135.11) in a research note on Monday, May 2nd. UBS Group cut their target price on shares of Sanofi from €122.00 ($129.79) to €121.00 ($128.72) and set a “buy” rating on the stock in a research report on Friday, April 8th. Finally, Barclays upped their price target on Sanofi from €90.00 ($95.74) to €105.00 ($111.70) in a research report on Thursday, April 14th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $99.86.
Shares of SNY stock opened at $56.29 on Wednesday. The stock has a market cap of $142.26 billion, a P/E ratio of 18.22, a price-to-earnings-growth ratio of 1.09 and a beta of 0.50. Sanofi has a 1 year low of $46.92 and a 1 year high of $58.10. The company has a current ratio of 1.44, a quick ratio of 1.03 and a debt-to-equity ratio of 0.25. The stock has a 50 day simple moving average of $53.33 and a 200 day simple moving average of $51.63.
The firm also recently announced an annual dividend, which will be paid on Wednesday, June 8th. Investors of record on Thursday, May 5th will be given a dividend of $1.7968 per share. This represents a yield of 2.7%. The ex-dividend date of this dividend is Wednesday, May 4th. Sanofi’s payout ratio is 40.78%.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Alliancebernstein L.P. increased its position in shares of Sanofi by 23.3% during the 3rd quarter. Alliancebernstein L.P. now owns 137,686 shares of the company’s stock valued at $6,638,000 after purchasing an additional 25,982 shares during the last quarter. US Bancorp DE raised its position in Sanofi by 2.6% in the 3rd quarter. US Bancorp DE now owns 62,420 shares of the company’s stock worth $3,010,000 after purchasing an additional 1,602 shares during the period. BOKF NA purchased a new position in shares of Sanofi in the third quarter worth about $632,000. American Century Companies Inc. lifted its position in Sanofi by 15.5% in the third quarter. American Century Companies Inc. now owns 233,358 shares of the company’s stock valued at $11,250,000 after purchasing an additional 31,240 shares during the last quarter. Finally, First Republic Investment Management Inc. boosted its position in Sanofi by 4.2% during the 3rd quarter. First Republic Investment Management Inc. now owns 89,507 shares of the company’s stock valued at $4,315,000 after buying an additional 3,598 shares during the period. Institutional investors and hedge funds own 12.82% of the company’s stock.
Sanofi Company Profile (Get Rating)
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
Read More
Receive News & Ratings for Sanofi Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sanofi and related companies with MarketBeat.com’s FREE daily email newsletter.
